Immuno-Oncology: Asgard Therapeutics

About this session

Asgard Therapeutics is a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy. The company builds on ground-breaking and proprietary reprogramming technologies to develop gene therapy products designed to recreate therapeutic immune cells in vivo, setting in motion efficient and personalized immune responses. Asgard advances in vivo direct reprogramming as a next-generation cell therapy, overcoming the traditional challenges of the cell therapy field.

Speaker

• CP

  Cristiana Pires

  Co-founder and CEO · Asgard Therapeutics

  Speaker